China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Asian Stocks Slide as Iran Tensions Escalate Despite Strong Weekly Gains 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Wall Street Futures Edge Higher as Iran Tensions and AI Optimism Shape Markets 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Saudi Aramco Q1 Profit Jumps 25% as Strait of Hormuz Crisis Reshapes Oil Exports 
Lula and Trump Talks Signal New Phase in Brazil-US Relations 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Asian Currencies Slip as US Dollar Gains on Rising Iran Tensions and Awaited Jobs Data 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Gold Prices Rise as Weaker Dollar and Iran Ceasefire Hopes Boost Safe-Haven Demand 
Malaysia Unveils Energy Security Plan Amid Iran Conflict and Rising Oil Costs 
Oil Prices Rise Amid Strait of Hormuz Tensions and U.S.-Iran Ceasefire Uncertainty 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Samsung Biologics revealed on Monday, Sept. 18, that it has closed a contract manufacturing organization deal (CMO) with Bristol-Myers Squibb to produce immunotherapy medications until 2030. The contract is said to be worth $242 million.
Bristol-Myers Squibb is one of the long-term customers of Samsung Biologics, so this is just another deal for a new production request. They have been working together for the CMO business since 2013. In any case, on the part of the Korean biopharmaceutical company, this contract has been added to its streak of wins for CMO projects this year alone.
Collectively, the company is close to hitting the KRW3 trillion or $2.26 billion mark for all of its deals so far in 2023. Reaching this amount is said to be a milestone for Samsung Biologics as it is happening for the first time.
As per The Korea Herald, as of September 2023, the Incheon-based biotechnology firm was able to secure contract manufacturing deals with 14 of the world’s top 20 pharmaceuticals. Novartis and Pfizer are the other major brands that signed large-scale agreements with the company.
Meanwhile, Samsung Biologics agreed to produce immunotherapies of Bristol-Myers Squibb. These will be manufactured in its fourth plant in the span of seven years.
An official of the biotech arm of the Samsung Group said, “Securing the latest deal was possible as Samsung Biologics has proved itself as a reliable contract manufacturer to its global partners, with its large production capacity, fast manufacturing speeds and consistent, high-quality output.”
“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” Samsung Biologics’ president and chief executive officer, John Rim, further said in a statement. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”
Photo by: Samsung Biologics Newsroom
